双能CT测量胰腺细胞外容积分数与糖耐量受损的相关性
本研究回顾性分析51例接受双能CT动态增强检查的患者,从平衡期碘图计算胰腺ECV分数。结果显示在肝硬化组胰腺ECV分数与HbA1c呈显著负相关(ρ=-0.346,p=0.048),非肝硬化组无显著相关;在HbA1c升高组,肝硬化患者胰腺ECV分数显著低于非肝硬化患者(0.247 vs 0.332,p=0.024),且胰腺截面积显著增大(2945 vs 1885 mm2,p=0.019)。提示DECT测量的胰腺ECV分数可能有助于阐明肝硬化患者糖耐量受损的病理生理机制。
要点
- 肝硬化合并糖耐量受损患者胰腺ECV分数降低,胰腺实质增大。
- 胰腺ECV分数与HbA1c的负相关仅见于肝硬化组。
- DECT碘图可定量胰腺ECV分数,辅助评估肝硬化糖代谢异常。
核心结论
- 肝硬化伴糖耐量受损患者中,DECT测量的胰腺ECV分数降低且胰腺实质增大。
- 胰腺ECV分数测量可能有助于阐明肝硬化患者糖耐量受损的病理生理机制。
研究设计与样本
- 回顾性研究,纳入2018年3月至2019年2月间接受双能模式对比增强动态CT检查的患者51例(中位年龄69岁,女性22例)。
- 从平衡期对比增强DECT图像生成的碘图上计算胰腺ECV分数,并测量胰腺截面积。
- 以HbA1c值评估糖耐量受损,比较肝硬化组与非肝硬化组。
关键影像表现/征象
- 肝硬化组胰腺ECV分数与HbA1c呈显著负相关(ρ=-0.346,p=0.048),非肝硬化组无显著相关(ρ=-0.086,p=0.734)。
- HbA1c升高组中,肝硬化患者胰腺ECV分数中位数0.247(IQR 0.098)显著低于非肝硬化患者0.332(IQR 0.113)(p=0.024)。
- HbA1c升高组中,肝硬化患者胰腺截面积中位数2945(IQR 904)mm2显著大于非肝硬化患者1885(IQR 909)mm2(p=0.019)。
临床应用与阅片要点
- 在肝硬化患者中,可尝试利用DECT碘图测量胰腺ECV分数,辅助评估糖耐量受损风险。
- 阅片时注意肝硬化患者胰腺形态学改变(体积增大)与ECV分数降低可能并存。
局限性
- 回顾性研究,样本量较小(51例)。
- 单中心研究,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the clinical value of measuring the ECV fraction of the pancreas by DECT in association with an impaired glucose tolerance (IGT) estimated by the hemoglobin A1C (HbA1C) value in patients with or without cirrhosis.
MATERIALS AND METHODS: This retrospective study included patients who underwent contrast-enhanced dynamic CT with dual-energy mode between March 2018 and February 2019. The ECV fraction of the pancreas was calculated from iodine map images created from equilibrium-phase contrast-enhanced DECT images. The cross-sectional areas of the pancreas were also measured.
RESULTS: In total, 51 patients were analyzed (median age, 69 years old; 22 women). The ECV fraction of the pancreas showed a significant negative correlation with the HbA1c value in the cirrhotic group (ρ=-0.346, p = 0.048), while there was no significant correlation in the non-cirrhotic group (ρ=-0.086, p = 0.734). In the elevated HbA1C group, the ECV fraction of the pancreas in the cirrhotic patients (median, 0.247; interquartile range [IQR], 0.098) was significantly lower than that in the non-cirrhotic patients (0.332, IQR 0.113) (p = 0.024). In the elevated HbA1C group, the cross-sectional area of the pancreas was significantly larger in the cirrhotic patients than that in the non-cirrhotic patients (median [IQR]; 2945 [904] vs. 1885 [909] mm2, p = 0.019).
CONCLUSION: A reduction in the ECV fraction of the pancreas measured by DECT as well as the enlargement of the pancreatic parenchyma was observed in cirrhotic patients with IGT. These findings suggest that the measurement of the pancreatic ECV fraction by DECT may help clarify the pathophysiology of IGT in patients with cirrhosis.
引用
- Kameda F, Tanabe M, Higashi M, et al. The extracellular volume fraction of the pancreas measured by dual-energy computed tomography: The association with impaired glucose tolerance. Eur J Radiol. 2021. PMID: 34020172. doi:10.1016/j.ejrad.2021.109775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。